Tag: Pregnancy and preeclampsia studies
Air pollutant exposure was linked to higher preeclampsia risk
—
in MedicineRetrospective cohort study linking ambient air pollutants to preeclampsia risk, identifying critical exposure windows and elevated vulnerability in assisted reproductive technology pregnancies.
History of preeclampsia linked to later cardiovascular risk
—
in MedicineRetrospective study demonstrates that preeclampsia significantly increases long-term risk of hypertension, cardiovascular disease, obesity, and metabolic complications in women.
Echocardiography showed worse hemodynamics with severe pregnancy hypertension
—
in MedicineEchocardiographic assessment reveals progressive systolic and diastolic hemodynamic alterations in hypertensive pregnancy correlating with disease severity and adverse outcomes.
Low-dose aspirin is recommended to prevent preeclampsia in high-risk pregnancy
—
in MedicineReview of aspirin’s pharmacological mechanisms and clinical evidence for low-dose therapy in pregnancy, emphasizing preeclampsia prevention and improved outcomes in high-risk populations.
Echocardiographic indicators predicted adverse outcomes in PIHS
—
in ObstetricsEchocardiographic parameters independently predict adverse pregnancy outcomes in women aged 35+ with pregnancy-induced hypertension, with combined assessment achieving excellent discrimination.
Hypertensive pregnancy linked to higher cardiac biomarker levels
—
in MedicineCross-sectional study of 312 pregnant women reveals progressive elevation of cardiac biomarkers including NT-proBNP and troponin-I across severity spectrum of hypertensive disorders.
Pregnancy-related coronary microvascular dysfunction remains poorly understood
—
in CardiologyCMD prevalence among pregnant women remains underrecognized; diagnostic methods and management approaches require pregnancy-specific validation and standardization to improve clinical outcomes.
Ugandan women with PPCM had high 6-month mortality and partial recovery
—
in MedicineProspective Ugandan cohort (n=80) with PPCM: baseline severe LV dysfunction, 7.5% six-month mortality, 10% intracardiac thrombus, 46.3% LV recovery; two-thirds received bromocriptine.
